Cargando…

Pharmacogenetic Risk Stratification in Angiotensin-Converting Enzyme Inhibitor-Treated Patients with Congestive Heart Failure: A Retrospective Cohort Study

BACKGROUND: Evidence for pharmacogenetic risk stratification of angiotensin-converting enzyme inhibitor (ACEI) treatment is limited. Therefore, in a cohort of ACEI-treated patients with congestive heart failure (CHF), we investigated the predictive value of two pharmacogenetic scores that previously...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nelveg-Kristensen, Karl Emil, Busk Madsen, Majbritt, Torp-Pedersen, Christian, Køber, Lars, Egfjord, Martin, Berg Rasmussen, Henrik, Riis Hansen, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669156/ https://www.ncbi.nlm.nih.gov/pubmed/26633885 http://dx.doi.org/10.1371/journal.pone.0144195

Ejemplares similares

Pharmacodynamic Impact of Carboxylesterase 1 Gene Variants in Patients with Congestive Heart Failure Treated with Angiotensin-Converting Enzyme Inhibitors
por: Nelveg-Kristensen, Karl Emil, et al.
Publicado: (2016)

SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril) -Induced Cough: a Pharmacogenetic Study
por: Luo, Jian-Quan, et al.
Publicado: (2015)

Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
por: Rasmussen, Henrik Berg, et al.
Publicado: (2023)

Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population‐Based Cohort Study
por: Thomsen, Reimar Wernich, et al.
Publicado: (2018)

Risk of death after first-time blood stream infection in incident dialysis patients with specific consideration on vascular access and comorbidity
por: Nelveg-Kristensen, Karl Emil, et al.
Publicado: (2018)

Angiotensin Converting Enzymes
por: Wong, Marty K.S.
Publicado: (2016)

Angiotensin converting enzyme
por: Wong, Marty Kwok-Shing
Publicado: (2021)

Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease
por: Ferreira de Oliveira, Fabricio, et al.
Publicado: (2016)

Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq
por: Al-Hussaniy, Hany A., et al.
Publicado: (2023)

Amplicon-Based NGS Panels for Actionable Cancer Target Identification in Follicular Cell-Derived Thyroid Neoplasia
por: Madsen, Majbritt Busk, et al.
Publicado: (2020)

Employment Status and Health Literacy in Denmark: A Population-Based Study
por: Svendsen, Ida W., et al.
Publicado: (2021)

Nucleoside analog GS‐441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid‐19
por: Rasmussen, Henrik Berg, et al.
Publicado: (2022)

WISH-R– a fast and efficient tool for construction of epistatic networks for complex traits and diseases
por: Carmelo, Victor A. O., et al.
Publicado: (2018)

Angiotensin-Converting Enzyme-2
por: Clarke, Nicola E., et al.
Publicado: (2013)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism
por: Meurs, Kathryn M, et al.
Publicado: (2017)

Dietary Potassium Downregulates Angiotensin-I Converting Enzyme, Renin, and Angiotensin Converting Enzyme 2
por: Vio, Carlos P., et al.
Publicado: (2020)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study
por: Olesen, Jonas Bjerring, et al.
Publicado: (2011)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Renin‐angiotensin aldosterone profile before and after angiotensin‐converting enzyme‐inhibitor administration in dogs with angiotensin‐converting enzyme gene polymorphism
por: Adin, Darcy, et al.
Publicado: (2020)

Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model
por: Oemrawsingh, Rohit M., et al.
Publicado: (2016)

Angiotensin-Converting Enzyme Inhibitors and Angioedema
por: Sánchez-Borges, Mario, et al.
Publicado: (2010)

Angiotensin-converting Enzyme Genetic Polymorphism
por: Wiwanitkit, Somsri, et al.
Publicado: (2014)

Genetic Hypothesis and Pharmacogenetics Side of Renin-Angiotensin-System in COVID-19
por: Gemmati, Donato, et al.
Publicado: (2020)

Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study
por: Charlot, Mette, et al.
Publicado: (2011)

Angiotensin converting enzime inhibitors : past, present and beyond /
Publicado: (1989)

Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema
por: Rasmussen, Eva Rye, et al.
Publicado: (2017)

Novel Genetic Causes of Gastrointestinal Polyposis Syndromes
por: Jelsig, Anne Marie, et al.
Publicado: (2021)

Angiotensin-converting enzyme 2 and new insights into the renin–angiotensin system
por: Lambert, Daniel W., et al.
Publicado: (2008)

Intrarenal Distributions and Changes of Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 in Feline and Canine Chronic Kidney Disease
por: MITANI, Sawane, et al.
Publicado: (2013)

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies
por: Kriszta, Gábor, et al.
Publicado: (2021)

Angiotensin-(1-7), Angiotensin-Converting Enzyme 2, and New Components of the Renin Angiotensin System
por: Trask, Aaron J., et al.
Publicado: (2009)

Dronedarone in patients with congestive heart failure: insights from ATHENA
por: Hohnloser, Stefan H., et al.
Publicado: (2010)

SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study
por: Husby, Anders, et al.
Publicado: (2021)

Corrigendum to “Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema”
por: Rasmussen, Eva Rye, et al.
Publicado: (2018)

Angiotensin-Converting Enzyme 2: The First Decade
por: Clarke, Nicola E., et al.
Publicado: (2012)

Angiotensin-I-converting enzyme and its relatives
por: Riordan, James F
Publicado: (2003)

Serum Angiotensin Converting Enzyme in Pemphigus Vulgaris
por: Robati, Reza M, et al.
Publicado: (2014)

Angiotensin Converting Enzyme Activity in Alopecia Areata
por: Namazi, Mohammad Reza, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_oeebdds8q79m9fuoap6e1o8iec